Colorectal cancer arises from complex genetic, epigenetic, and molecular defects that result in the sequential and cumulative deregulation of cellular functions affecting cell proliferation and differentiation, survival, angiogenesis, and metastasis. Among the oncogenes and tumor suppressor genes involved, the caudal-type homeobox transcription factor Cdx2 plays a key role in intestinal cell differentiation, proliferation, and is implicated in colorectal cancer progression. Loss or depletion of Cdx2 occurs in human colon tumors, and when induced in transgenic animals is associated with the emergence of preneoplastic lesions leading to the formation of proliferative adenoma at the adenocarcinoma transition. In the upper digestive tract, Cdx2 is now considered as an early differentiation marker of intestinal metaplasia in Barrett's epithelium and inflammatory esophageal mucosa. These pathological situations imply that both transcriptional and post-transcriptional mechanisms controlling Cdx2 levels are likely to play a key role in the determination of intestinal cell fate, differentiation and transformation. Hence, the first paper in this issue of Oncogene (Gross et al., 2005) reveals a novel and important mechanism of regulation for the Cdx2 transcription factor. This occurs via phosphorylation of the Cdx2 protein at serine 281 by cyclin-dependent kinase 2 (Cdk2), a checkpoint cell cycle regulator, controlled by cyclins A and E at the G1/S and S/G2 transitions. The Cdk2-mediated phosphorylation of Cdx2 coordinates its polyubiquitination and degradation by the proteasome. The serine residue identified as the essential target is part of a conserved motif of four evenly spaced serines (the 4S motif) similar to the one controlling b-catenin degradation by the proteasome pathway.
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These findings confirm and extend those recently reported by Boulanger et al. (2005) who showed that Cdk2 interacts with and phosphorylates Cdx2, and that in human colorectal cancer cells, a combination of the proteasome inhibitor MG132 with the selective Cdk inhibitor Roscovitine (Meijer et al., 1997) remarkably increased nuclear Cdx2 levels. Gross et al. also explored the functional consequences of replacing the serines in the 4S motif by alanines, showing impacts at Cdx2 transcriptional activity and suppression of colony formation in a transformation assay.
Taking a broader perspective, actual and putative molecular interactions and functional regulations between Cdx2, Cdk2-cyclins A/E complexes, cell cycle inhibitors and tumor suppressors p27 and p21, and other Cdk2-associated proteins and signaling cascades, could also help to explain their relative implication in colon cancer predisposition and progression. Notably, these molecular scaffolds and phosphorylation-dephosphorylation reactions at serine residues and several other motifs can take place, following nuclear importexport mechanisms, and upstream mitogenic stimuli triggered by transforming growth factors and oncogenes. The oncogenicity of the cyclin A and E-dependent Cdk2 kinase on Cdx2 levels is reminiscent of its impact on several tumor suppressors and transcription factors operating at the proliferationdifferentiation interface, such as MyoD, p27, and pRb1, a gatekeeper for entry into the cell cycle functioning as an E2F-sequestering antioncogene. Moreover, high levels of Cdk2 are often observed in colon cancer, consistent with amplification of the c-myc oncogene, acting as a transcription factor for the CDK2 gene.
These remarkable findings bring new avenues on the mechanisms regulating the proliferation-differentiation balance in gut epithelia, through a fine tuning of the Cdx2 tumor suppressor levels during intestinal stem cell self-renewal, epithelial cell sorting from the proliferative compartment, and neoplasia. Invalidation of the Cdx2 tumor suppressor can be accomplished by defective expression of the CDX2 gene, nuclear depletion of this transcription factor by abnormal nuclear export, and proteasome-mediated degradation in the cytoplasm. In that respect, a better knowledge on the nucleocytoplasmic shuttling of Cdx2 and its molecular partners is a prerequisite to better characterize the Cdk2 and Cdx2 signaling pathways. Since high levels of the nuclear export factor CRM1 are observed in the cytoplasm of mitotic cells, one can postulate that Cdk2-mediated phosphorylation of Cdx2 mediates its binding to and recognition by CRM1 and might constitute part of the molecular platform used to direct Cdk2-phosphorylated Cdx2 toward the proteasome. In this case, sequestration of Cdx2 by CRM1 in the cytoplasm will prevent translocation of the transcription factor in the nucleus. Since serine 281 is located downstream of the DNAbinding domain of the C-terminal end of Cdx2 and is a consensus and putative phosphorylation site for other protein kinases such as ERK and p38 MAPK/ SAPK, as well as GSK-3b, potential crosstalks between these pathways and the Cdk2-Cdx2 connection should be considered. Both ERK and p38 are implicated in colon cancer progression, as well as the canonical Wnt pathways targeting GSK-3b inhibition and protection of the b-catenin transcription factor from its degradation by the proteasome. Inappropriate activation of the Wnt pathway often observed in sporadic and familial colorectal cancers is associated with high levels of the transcription factor b-catenin in the cytoplasm and nucleus, and activation of several b-catenin-dependent promoter genes involved in cell proliferation, transformation, and inflammation. Other mechanisms using non-Wnt pathways and targeting GSK-3b inhibition are potential candidates for these connections and fine tuning of Cdx-2 levels at the proliferation and differentiation interface. Investigations aimed to evidence nuclear and cytoplasmic complexes between resident Cdk2/ Cdx2 and CRM1 or other partners will bring new informations on these scenario.
Molecular identification of signaling intermediates at the Cdk2/ Cdx2 pathways and crossroads regulating cell proliferation, differentiation, and apoptosis will help to further characterize their impact on the stability and function of Cdx2 and several tumor suppressors and oncogenes. This knowledge will help to design new molecular interventions and therapeutic strategies able to slow down cancer hyperproliferation and to induce terminal differentiation in colorectal tumors. Such a prediction has been recently validated by induction of postmitotic differentiated mucous-secreting goblet cells after conditional removal of the common Notch pathway transcription factor CSL-RBP-J ? or Notch blockade by the gamma-secretase inhibitor dibenzazepine (van Es et al., 2005) .
